Sökning: onr:"swepub:oai:DiVA.org:uu-315064" > Telotristat Ethyl, ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 04804naa a2200493 4500 | |
001 | oai:DiVA.org:uu-315064 | |
003 | SwePub | |
008 | 170301s2017 | |||||||||||000 ||eng| | |
024 | 7 | a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-3150642 URI |
024 | 7 | a https://doi.org/10.1200/JCO.2016.69.27802 DOI |
040 | a (SwePub)uu | |
041 | a engb eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Kulke, Matthew H.u Dana Farber Canc Inst, Boston, MA 02115 USA.4 aut |
245 | 1 0 | a Telotristat Ethyl, a Tryptophan Hydroxylase Inhibitor for the Treatment of Carcinoid Syndrome |
264 | 1 | c 2017 |
338 | a print2 rdacarrier | |
520 | a Purpose Preliminary studies suggested that telotristat ethyl, a tryptophan hydroxylase inhibitor, reduces bowel movement (BM) frequency in patients with carcinoid syndrome. This placebo-controlled phase III study evaluated telotristat ethyl in this setting. Patients and Methods Patients (N = 135) experiencing four or more BMs per day despite stable-dose somatostatin analog therapy received (1: 1: 1) placebo, telotristat ethyl 250 mg, or telotristat ethyl 500 mg three times per day orally during a 12-week double-blind treatment period. The primary end point was change from baseline in BM frequency. In an open-label extension, 115 patients subsequently received telotristat ethyl 500 mg. Results Estimated differences in BM frequency per day versus placebo averaged over 12 weeks were -0.81 for telotristat ethyl 250 mg (P < .001) and -0.69 for telotristat ethyl 500 mg (P,.001). At week 12, mean BM frequency reductions per day for placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg were -0.9, -1.7, and -2.1, respectively. Responses, predefined as a BM frequency reduction >= 30% from baseline for >= 50% of the double-blind treatment period, were observed in 20%, 44%, and 42% of patients given placebo, telotristat ethyl 250 mg, and telotristat ethyl 500 mg, respectively. Both telotristat ethyl dosages significantly reduced mean urinary 5-hydroxyindole acetic acid versus placebo at week 12 (P < .001). Mild nausea and asymptomatic increases in gamma-glutamyl transferase were observed in some patients receiving telotristat ethyl. Follow-up of patients during the open-label extension revealed no new safety signals and suggested sustained BM responses to treatment. Conclusion Among patients with carcinoid syndrome not adequately controlled by somatostatin analogs, treatment with telotristat ethyl was generally safe and well tolerated and resulted in significant reductions in BM frequency and urinary 5-hydroxyindole acetic acid. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng |
700 | 1 | a Hoersch, Dieteru Zentralklinik Bad Berka, Bad Berka, Germany.4 aut |
700 | 1 | a Caplin, Martyn E.u Royal Free Hosp, London, England.4 aut |
700 | 1 | a Anthony, Lowell B.u Univ Kentucky, Lexington, KY USA.4 aut |
700 | 1 | a Bergsland, Emilyu Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.4 aut |
700 | 1 | a Öberg, Kjellu Uppsala universitet,Endokrin tumörbiologi4 aut0 (Swepub:uu)kjellob |
700 | 1 | a Welin, Staffanu Uppsala universitet,Institutionen för medicinska vetenskaper4 aut0 (Swepub:uu)stafweli |
700 | 1 | a Warner, Richard R. P.u Icahn Sch Med Mt Sinai, New York, NY 10029 USA.4 aut |
700 | 1 | a Lombard-Bohas, Catherineu Hosp Civils Lyon, Hop Edouard Herriot, Lyon, France.4 aut |
700 | 1 | a Kunz, Pamela L.u Stanford Univ, Palo Alto, CA 94304 USA.4 aut |
700 | 1 | a Grande, Enriqueu Hosp Univ Ramon y Cajal, Madrid, Spain.4 aut |
700 | 1 | a Valle, Juan W.u Univ Manchester, Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England.4 aut |
700 | 1 | a Fleming, Douglasu Ipsen Biosci, Cambridge, MA USA.4 aut |
700 | 1 | a Lapuerta, Pablou Lexicon Pharmaceut, The Woodlands, TX USA.4 aut |
700 | 1 | a Banks, Phillipu Lexicon Pharmaceut, The Woodlands, TX USA.4 aut |
700 | 1 | a Jackson, Shannau Lexicon Pharmaceut, The Woodlands, TX USA.4 aut |
700 | 1 | a Zambrowicz, Brianu Lexicon Pharmaceut, The Woodlands, TX USA.4 aut |
700 | 1 | a Sands, Arthur T.u Lexicon Pharmaceut, The Woodlands, TX USA.4 aut |
700 | 1 | a Pavel, Marianneu Charite, Berlin, Germany.4 aut |
710 | 2 | a Dana Farber Canc Inst, Boston, MA 02115 USA.b Zentralklinik Bad Berka, Bad Berka, Germany.4 org |
773 | 0 | t Journal of Clinical Oncologyg 35:1, s. 14-23q 35:1<14-23x 0732-183Xx 1527-7755 |
856 | 4 8 | u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-315064 |
856 | 4 8 | u https://doi.org/10.1200/JCO.2016.69.2780 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy